Background: Among the many cannabinoids in the cannabis plant, cannabidiol (CBD) is a
compound that does not produce the typical subjective effects of marijuana. Objectives: The …

The interest in cannabis-based products for the treatment of refractory epilepsy has
skyrocketed in recent years. Marijuana and other cannabis products with high content in Δ …

Cannabidiol (CBD) is a major active component of the Cannabis plant, which, unlike
tetrahydrocannabinol (THC), is devoid of euphoria-inducing properties. During the last 10 …

Cannabis can synthetize more than 400 compounds, including terpenes, flavonoids, and
more than 100 phytocannabinoids. The main phytocannabinoids are Δ-9 …

Drug treatments available for the management of substance use disorders (SUD) present
multiple limitations in efficacy, lack of approved treatments or alarming relapse rates. These …

Epilepsy is a neurological disorder characterized by the presence of seizures and
neuropsychiatric comorbidities. Despite the number of antiepileptic drugs, one-third of …

Cannabidiol (CBD), the main nonpsychotomimetic compound from Cannabis sativa, inhibits
experimental seizures in animal models and alleviates certain types of intractable epilepsies …

Significant limitations with the currently available antidepressant treatment strategies have
inspired research on finding new and more efficient drugs to treat depression. Cannabidiol …

Several new antiepileptic medicines became available for clinical use in the last two
decades. However, the prognosis of epilepsy remains unchanged, with approximately one …

The aberrant accumulation of disease-specific protein aggregates accompanying cognitive
decline is a pathological hallmark of age-associated neurological disorders, also termed as …